Evidence map›Paper›PMID 36221143›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.

Jake Sheraj Jacob, Anjiya Shaikh, Karthik Goli, Nicole E Rich, Jihane N Benhammou, Aijaz Ahmed, Donghee Kim, Abbas Rana, John A Goss, Susanna Naggie and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Jake Sheraj JacobDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
Anjiya ShaikhDepartment of Internal Medicine, University of Connecticut, Mansfield, Connecticut, USA.
Karthik GoliDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
Nicole E RichDivision of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jihane N BenhammouDivision of Gastroenterology and Hepatology, University of California, Los Angeles, California, USA.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Donghee KimDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
Abbas RanaHepatology Program, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA.
John A GossHepatology Program, Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA.
Susanna NaggieDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Tzu-Hao LeeDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
Fasiha KanwalDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
George CholankerilDepartment of Internal Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.
Baylor College of Medicine · USStanford University · USDuke University · USThe University of Texas Southwestern Medical Center · USUniversity of California, Los Angeles · USUniversity of Connecticut · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
Risk Stratification for and Early Detection of Liver CancerU01CA230997 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jagpreet Chhatwal, Hashem B El-Serag · 2018 to 2026
$6.4M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
NCI NIH HHS R01 CA256977NCI NIH HHS U01 CA230997NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

backgroundPeople with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed the treatment landscape for HIV and HCV, respectively, but their impact on LT outcomes remains unclear.

methodsThis retrospective analysis of adults with HIV monoinfection (n = 246) and HIV/HCV coinfection (n = 286) who received LT compared mortality in patients with HIV who received LT before versus after approval of INSTIs and in patients with HIV/HCV coinfection who received LT before versus after approval of DAAs. In secondary analysis, we compared the outcomes in the different eras with those of propensity score-matched control cohorts of LT recipients without HIV or HCV infection.

resultsLT recipients with HIV monoinfection did not experience a significant improvement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard ratio [aHR], 0.70 [95% confidence interval {CI}, .36-1.34]). However, recipients with HIV/HCV coinfection in the DAA era had a 47% reduction (aHR, 0.53 [95% CI, .31-9.2] in 1-year mortality compared with coinfected recipients in the pre-DAA era. Compared to recipients without HIV or HCV, HIV-monoinfected recipients had higher mortality during the pre-INSTI era, but survival was comparable between groups during the INSTI era. HIV/HCV-coinfected recipients also experienced comparable survival during the DAA era compared to recipients without HCV or HIV.

conclusionsPost-LT survival for people with HIV monoinfection and HIV/HCV coinfection has improved with the introduction of INSTI and DAA therapy, suggesting that LT has become safer in these populations.

Indexed as

CoinfectionHepatitis CHepatitis C, ChronicHIV InfectionsLiver TransplantationAdultAntiviral AgentsHepacivirusHIVHumansIntegrasesRetrospective StudiesAntiviral AgentsIntegrasesDAAHCVHIVINSTItransplant

Identifiers

PMID36221143
PMCPMC10169442
OpenAlexW4304589270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.